PassFinals
Gastroenterology & Nutrition

MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is hepatic steatosis with cardiometabolic risk; most people are asymptomatic, so the clinical priority is identifying advanced fibrosis and reducing liver and cardiovascular risk.

In a nutshell

MASLD is steatosis with cardiometabolic risk, formerly called NAFLD. Most people are asymptomatic, and normal liver enzymes do not exclude disease. The important question is fibrosis risk: use the local sequential non-invasive pathway, with NICE ELF 10.51 or above indicating advanced fibrosis and hepatology referral. Treat with supported diet/activity and weight management plus diabetes, blood-pressure and lipid control; statins should not be withheld solely for mild transaminase elevation.

Classic presentation

An asymptomatic person with obesity and type 2 diabetes has a fatty liver on ultrasound and normal or mildly abnormal liver tests; the next step is fibrosis risk assessment, not reassurance.

Key points

  • MASLD is the current term for metabolic dysfunction-associated steatotic liver disease; NICE NG49 still uses the legacy NAFLD title while the formal MASLD update is in development.
  • Normal ALT/AST does not exclude MASLD or advanced fibrosis.
  • Use sequential non-invasive fibrosis assessment: a validated simple score where locally used, then ELF or elastography; NICE ELF 10.51 or above means advanced fibrosis.
  • Support sustainable diet, activity and weight management; avoid unsupervised extreme diets or a single promised weight-loss threshold.
  • Assess and treat cardiovascular/metabolic risk; do not routinely exclude statins when transaminases are below 3 times the upper limit of normal.
  • Advanced fibrosis or cirrhosis needs hepatology follow-up and complication surveillance.
  • Do not present draft or international MASH drugs as routine UK treatment; specialist prescribing follows current NICE, BNF and commissioning.

First-line investigation

Review metabolic and alcohol context, liver aetiology screen, liver imaging/LFTs and sequential non-invasive fibrosis assessment; do not use normal LFTs to rule out disease.

Management

Confirm context and assess fibrosis

  • Review steatosis, alcohol, metabolic risk and alternative liver disease; use the local sequential non-invasive fibrosis pathway and refer high-risk/indeterminate results.1,3

Treat weight, diet and activity

  • Offer individualised, sustainable diet and physical-activity support with long-term follow-up, taking account of comorbidity, finances, culture and disordered-eating risk.1,5,3

Reduce cardiovascular and metabolic risk

  • Optimise diabetes, blood pressure, lipids, kidney risk and smoking; do not routinely withhold statins for transaminases below 3 times the upper limit of normal.4,3

Use specialist drug therapy cautiously

  • Reserve liver-directed pharmacotherapy for hepatology-led decisions under current NICE/BNF and local commissioning; emerging or draft therapies are not routine UK practice.1,2,8

Monitor fibrosis and cirrhosis complications

  • Reassess low-risk fibrosis at the NICE interval, follow advanced fibrosis in hepatology and apply the cirrhosis pathway for HCC, varices, portal hypertension and decompensation.1,6,3

Exam traps

  • A fatty liver is not synonymous with advanced fibrosis; stage fibrosis explicitly.
  • Normal transaminases do not exclude MASLD, MASH or advanced fibrosis.
  • Do not define MASLD by simply saying 'no alcohol'; alcohol and metabolic risk can overlap and must be quantified.
  • Statins are not routinely contraindicated in MASLD with mild transaminase elevation.
  • ELF 10.51 or above is the NICE threshold for advanced fibrosis; do not invent alternative cut-offs.
  • Pioglitazone/vitamin E or newer liver-directed medicines are specialist decisions, not routine primary-care prescriptions.
  • Cirrhosis changes the follow-up pathway: add HCC, variceal and decompensation surveillance.

Illustrations

Steatotic liver disease with fibrosis on histologyTrichrome-stained liver tissue showing steatosis and fibrous tissue, used to illustrate that fibrosis stage—not the visual amount of fat alone—drives prognosis and referral.Nephron, Wikimedia Commons · CC-BY-SA-3.0

Key sources

  1. NICE NG49, Non-alcoholic fatty liver disease: assessment and management (Current operative NICE guideline; last reviewed 24 October 2024 while a partial MASLD update is developed)Updated 24 Oct 2024
  2. NICE GID-NG10434, Metabolic Dysfunction-Associated Steatotic Liver Disease (Guideline in development; expected publication 27 July 2027, partially updating NG49)Updated 11 Mar 2026
  3. BASL/BSG NAFLD Special Interest Group quality standards (Lancet Gastroenterology and Hepatology 2022; sequential fibrosis testing and holistic cardiometabolic care)Updated 1 Jan 2022
  4. NICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification (Current lipid and statin recommendations, including raised transaminase safety)Updated 1 Dec 2023
  5. NICE NG246, Overweight and obesity management (Current individualised diet, activity and supported weight-management recommendations; last updated 8 January 2026)Updated 8 Jan 2026
  6. NICE NG50, Cirrhosis in over 16s: assessment and management (Cirrhosis monitoring and complication-surveillance pathway)
  7. BNF, statins and lipid-regulating drugs (Current prescribing, adverse-effect and interaction information)
  8. BNF, pioglitazone and vitamin E prescribing information (Current contraindications, cautions and licensed/off-label status must be checked before specialist prescribing)

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.